Almirall Accelerates Antibody Discovery and Signs Two New Agreements

Almirall expects to be a major player in antibody discovery. The Catalan pharmaceutical company, specialized in skin health, has reached a multi-year licensing agreement with Ablexis, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody discovery, and a research collaboration with AlivaMab Discovery Services (ADS), a company specialized in the discovery and engineering of therapeutic antibodies.

The Spanish company obtains non-exclusive rights to use Ablexis’ AlivaMab Mouse technology for the discovery, development and commercialization of innovative antibody drugs, according to the terms of the agreement.

In addition, Almirall will collaborate with AlivaMab Discovery Services to conduct research, leveraging ADS’ expertise in antibody discovery and engineering using the AlivaMab Mouse technology, a platform for the generation of human therapeutic antibodies.

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Almirall reaches a multi-target licensing agreement with Ablexis and a collaboration with AlivaMab Discovery

“These agreements are related to Almirall’s goal of developing innovative treatments for patients suffering from severe skin diseases; AlivaMab Discovery Services’ extensive expertise in antibody discovery and engineering coupled with Almirall’s experience in medical dermatology will significantly accelerate the development of differentiated treatments to help patients achieve their goal of living a healthy life,” states Thomas Huber, Almirall’s chief research officer.

Almirall, founded in 1943 and headquartered in Barcelona, is listed on the Spanish Stock Exchange and is a member of the Ibex 35. The company currently has a direct presence in 21 countries and strategic agreements in more than 70 countries through 13 subsidiaries, with approximately 1,800 employees. Almirall’s total revenues in 2020 were $910 million (€814.5 million).

Ablexis created and non-exclusively licensed AlivaMab Mouse, a set of unique and proprietary next-generation transgenic mice, as a platform for the discovery of therapeutic human antibodies. Ablexis has licensing agreements with dozens of companies, including pharmaceutical, biotech, and other entities. Ablexis continues to make AlivaMab Mouse available through non-exclusive licenses.

ADS focuses on rapid and efficient delivery of antibodies, with functional level characterization, kinetics and development capabilities, and engineering for advanced modalities, including multispecifics and CARs. The ADS team’s expertise in antibody drug discovery and development comes from many of the world’s top fifteen pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer and Roche/Genentech, and translates into more than 500 research programs and 35 clinical candidates.

__

(Featured image by Ousa Chea via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.